A phase i trial combining oral cisplatin (CP Ethypharm) with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma

Radiotherapy and Oncology

Volumn 98, Issue 1, 2011, Pages 42-47

  Tao, Yungan ^a   Rezaï, Keyvan ^b   Brain, Etienne ^b   Etessami, Atoussa ^a   Lusinchi, Antoine ^a   Temam, Stephane ^a   Urien, Saik ^b   Van, Marie Louise Vo ^c   Vauzelle Kervroedan, Françoise ^c   Lokiec, François ^b   Daly Schveitzer, Nicolas ^a   Bourhis, Jean ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE RENÉ HUGUENIN   (France)

^c Ethypharm   (France)

Author keywords

Chemotherapy; Head and neck cancer; Oral cisplatin; Phase I; Radiotherapy

Indexed keywords

CISPLATIN; CP ETHYPHARM; ONDANSETRON; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; CREATININE BLOOD LEVEL; DERMATITIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG TOLERANCE; DYSPHAGIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CARCINOMA; HEARING LOSS; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SQUAMOUS CELL CARCINOMA;

ADMINISTRATION, ORAL; CARCINOMA; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS, SQUAMOUS CELL; RADIOTHERAPY DOSAGE;

EID: 78651355624     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2010.11.008     Document Type: Article

References (21)

1. R.I. Haddad, and D.M. Shin Recent advances in head and neck cancer N Engl J Med 359 2008 1143 1154
2. J.P. Pignon, J. Bourhis, C. Domenge, and L. Designe Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer Lancet 355 2000 949 955
3. J.P. Pignon, A. le Maitre, E. Maillard, and J. Bourhis Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17, 346 patients Radiother Oncol 92 2009 4 14
4. A.A. Forastiere, H. Goepfert, and M. Maor Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer N Engl J Med 349 2003 2091 2098 (Pubitemid 37464533)
5. D.J. Adelstein, Y. Li, and G.L. Adams An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer J Clin Oncol 21 2003 92 98
6. J. Bernier, C. Domenge, and M. Ozsahin Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer N Engl J Med 350 2004 1945 1952 (Pubitemid 38580197)
7. J.S. Cooper, T.F. Pajak, and A.A. Forastiere Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck N Engl J Med 350 2004 1937 1944
8. L. Marcu, T. van Doorn, and I. Olver Cisplatin and radiotherapy in the treatment of locally advanced head and neck cancer - a review of their cooperation Acta Oncol 42 2003 315 325 (Pubitemid 36851149)
9. P. Huguenin, K.T. Beer, and A. Allal Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy J Clin Oncol 22 2004 4665 4673 (Pubitemid 41185075)
10. B. Jeremic, Y. Shibamoto, B. Stanisavljevic, L. Milojevic, B. Milicic, and N. Nikolic Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial Radiother Oncol 43 1997 29 37 (Pubitemid 27191976)
11. B. Jeremic, Y. Shibamoto, and B. Milicic Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial J Clin Oncol 18 2000 1458 1464 (Pubitemid 30205391)
12. M.R. Posner, A.T. Skarin, J. Clark, T.J. Ervin, and I. Phase Study of continuous-infusion cisplatin Cancer Treat Rep 70 1986 847 850
13. C. Boni, G. Moretti, and L. Savoldi Neoadjuvant chemotherapy with continuous infusion of cisplatin and fluorouracil in stage II-IV, M0 squamous cell carcinoma of the head and neck Tumori 82 1996 567 572 (Pubitemid 27120802)
14. A.F. LeRoy, M.L. Wehling, and H.L. Sponseller Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry Biochem Med 18 1977 184 191 (Pubitemid 8213839)
15. S. Urien, E. Brain, and R. Bugat Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients Cancer Chemother Pharmacol 55 2005 55 60 (Pubitemid 40064496)
16. D. Steinmann, B. Cerny, J.H. Karstens, and M. Bremer Chemoradiotherapy with weekly cisplatin 40 mg/m(2) in 103 head-and-neck cancer patients: a cumulative dose-effect analysis Strahlenther Onkol 185 2009 682 688
17. K.K. Ang, J. Harris, and A.S. Garden Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14 J Clin Oncol 23 2005 3008 3015 (Pubitemid 46224121)
18. G. Gasparini, G. Recher, and A. Testolin Synchronous radiotherapy and chemotherapy with cisplatin in the management of locally advanced or recurrent head and neck cancer Am J Clin Oncol 15 1992 242 249
19. P.B. Chougule, S. Suk, and Q.D. Chu Cisplatin as a radiation sensitizer in the treatment of advanced head and neck cancers. Results of a phase II study Cancer 74 1994 1927 1932 (Pubitemid 24301856)
20. J. Bonneterre, B. Chevalier, C. Focan, L. Mauriac, M. Piccart, and I. Phase And pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC) Ann Oncol 12 2001 1683 1691 (Pubitemid 34105657)
21. A. Depierre, G. Freyer, and J. Jassem Oral vinorelbine: feasibility and safety profile Ann Oncol 12 2001 1677 1681 (Pubitemid 34105656)